2019-04-29 16:00Financial Performance - The company's operating revenue for Q1 2019 was ¥1,023,118,395.29, representing a 6.65% increase compared to ¥798,062,177.39 in the same period last year[8]. - Net profit attributable to shareholders was ¥507,033,390.57, a significant increase of 636.43% from ¥41,988,171.45 in the previous year[8]. - The basic earnings per share rose to ¥0.4065, up 636.41% from ¥0.0337 in the same period last year[8]. - Total revenue increased significantly to 580,828,899.53, up 469.56% compared to the previous year[24]. - Net profit reached 494,548,778.62, representing a 593.02% increase year-over-year[24]. - Operating profit surged to 580,555,945.28, a 477.51% increase from the same period last year[24]. - The total comprehensive income for the current period was ¥483,170,110.98, compared to a loss of ¥65,759,857.72 in the previous period, showing a significant turnaround[81]. Cash Flow - The net cash flow from operating activities was -¥138,180,573.42, worsening by 80.53% compared to -¥48,225,972.78 in the previous year[8]. - Cash flow from operating activities decreased to -138,180,573.42, a decline of 80.53% compared to the previous year[24]. - Cash flow from investing activities also fell to -99,612,740.75, down 51.61% year-over-year[24]. - Cash flow from financing activities saw a significant drop to -593,869,140.67, a decrease of 574.54% compared to the previous year[24]. - The net increase in cash and cash equivalents was -837,713,560.20, reflecting a 3041.64% decline year-over-year[24]. - The ending balance of cash and cash equivalents was 1,280,195,092.57, down from 3,564,354,461.78 in the previous period[96]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,443,223,483.47, a decrease of 1.55% from ¥13,655,079,889.35 at the end of the previous year[8]. - The company's cash and cash equivalents decreased by 39.66% to CNY 1,280,300,092.57 due to repayment of bank loans and investment payments[22]. - The company's total liabilities decreased significantly by 98.51% to CNY 7,234,558.72 due to repayment of bank loans[22]. - Total liabilities decreased from CNY 7,410,333,285.80 to CNY 6,703,225,478.54, a reduction of approximately 9.5%[62]. - Total equity increased from CNY 6,244,746,603.55 to CNY 6,739,998,004.93, reflecting an increase of approximately 7.9%[64]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,804[12]. - The top shareholder, Shenzhen Lerun Technology, held 38.01% of the shares, totaling 474,029,899 shares[12]. - The company completed the issuance of non-public corporate bonds, raising a total of 700 million RMB with a final coupon rate of 5.5%[30]. Investments and Expenditures - Long-term equity investments increased by 142.30% to CNY 1,132,230,071.26 as a result of losing control over Junshengtai and adjusting the remaining equity value[22]. - Research and development expenses decreased by 35.08% to CNY 39,576,899.12, attributed to reduced R&D costs at subsidiary Tiandao Pharmaceutical[22]. - The company has made significant investments in equity partnerships, totaling 286.8 million RMB and 340.8 million RMB in various investment funds[38]. Future Plans and Strategies - The company plans to focus on market expansion and new product development as part of its future strategy[82].